Visualize HL7 Example and Test Instances (vi7eti), pronounced /viːˈsɛtiː/
Disclaimer: FOR TEST AND EXAMPLE PURPOSES ONLY! These web pages are not intended to be used as a source of information on medicines. The web pages are not kept up to date and are for demonstration purposes only. For up-to-date information on a medicine, please consult www.ema.europa.eu/medicines or the package leaflet of your medicine.
BACK TO LIST

Laboratory Report

Patient
Name: Smith, , Timothy,
DOB: 10-SEP-1941 (Age: 84)
Gender: male
Address:
9 Jeffrey orchard
NW1 North Joshuaville (United Kingdom)
ID: 8029-862360-6 (ECI)
Report
Date: 28-DEC-2020
Laboratory
dr Ample, Ex
Laboratoire Central Européenne
Boulevard du Jardin Botanique 32
1000 Brussels (Belgium)
Requested by
Evelina Children's Hospital
SE1 7 London (United Kingdom)
Specimen
Collected: 28-DEC-2020

Chemistry

Test 28-DEC-2020 Reference Range Unit
Hemoglobin A1c/Hemoglobin.total in Blood 5.5 4.5 - 6.4 %
Glucose [Mass/volume] in Blood 130.5 70 - 140 mg/dL
Urea nitrogen [Mass/volume] in Blood 8.8 7 - 25 mg/dL
Creatinine [Mass/volume] in Blood 0.7 0.6 - 1.3 mg/dL
Calcium [Mass/volume] in Blood 9.1 8.5 - 10.5 mg/dL
Sodium [Moles/volume] in Blood 143.5 135 - 145 mmol/L
Potassium [Moles/volume] in Blood 4.3 3.5 - 5.1 mmol/L
Chloride [Moles/volume] in Blood 103.4 98 - 107 mmol/L
Carbon dioxide, total [Moles/volume] in Blood 24.9 22 - 29 mmol/L
Cholesterol [Mass/volume] in Serum or Plasma 247.0 H 0 - 200 mg/dL
Triglyceride [Mass/volume] in Serum or Plasma 497.6 H 0 - 199 mg/dL
Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay 120.1 0 - 130 mg/dL
Cholesterol in HDL [Mass/volume] in Serum or Plasma 27.4 L 40 - 100 mg/dL
Microalbumin/Creatinine [Mass Ratio] in Urine 14.7 0 - 30 mg/g

Annotation

Conclusion and Recommendations based on this report and previous findings known to us
The patient"s renal function, glucose metabolism, and electrolytes are within normal limits. However, there is significant dyslipidemia with elevated total cholesterol and triglycerides, low HDL, and borderline LDL, increasing cardiovascular risk. HbA1c is in the non-diabetic range. Recommend clinical follow-up for lipid management and cardiovascular risk reduction.